clear
Thursday May 26th, 2016 5:05PM

New drug, study method show breast cancer promise

By The Associated Press
SAN ANTONIO (AP) -- A novel and faster way to test cancer drugs has yielded its first big result: An experimental medicine that shows promise against a hard-to-treat form of breast cancer.

The method involves studying drugs in small groups of people to quickly separate winners from duds.

Bringing a new cancer drug to market usually takes more than a decade and tests in thousands of patients, and costs more than $1 billion. Companies can't afford many studies like that and patients can't afford to wait years for potentially life-saving new medicines, said Don Berry, a biostatistician at the University of Texas MD Anderson Cancer Center.

He helped design the novel analytical method used in a study discussed Friday at the San Antonio Breast Cancer Symposium, an international conference on the disease.

Researchers testing a drug usually don't see results until they're all in, to prevent biasing the study. But several years ago, an unusual partnership decided to try a new way. It involves the National Cancer Institute, the Food and Drug Administration, drug companies, dozens of cancer research centers and charitable foundations.

The study, called I-SPY 2, enrolls small groups of women on experimental drugs or combinations, then gives them surgery to see what effect treatment had. The best result is a complete response, where no signs of cancer remain. Each patient's results are analyzed as they come in, and advanced statistical methods are used to calculate probabilities that the drug would help in various situations, depending on which women had a complete response.

"This allows us to learn and adapt from each patient as the study goes on," and results on early participants guide treatment that later participants get, said Dr. Hope Rugo of the University of California, San Francisco. When enough evidence indicates a high probability of success, the drug "graduates" to final-phase testing aimed at winning FDA approval.

On Friday, Rugo gave results on the first of seven drugs being tested - veliparib, made by AbbVie Inc., a North Chicago, Ill., company recently spun off from Abbott Laboratories. It is in a new class of experimental medicines called PARP inhibitors, which target an enzyme cancer relies on to grow.

The I-SPY 2 testing suggests that adding the chemotherapy drug carboplatin and veliparib to usual chemo before surgery improved outcomes for women with "triple negative" breast cancer - tumors that are not fueled by estrogen, progesterone or the gene that the medicine Herceptin targets.

Up to 20 percent of breast cancers are this type, and they're more common in young women, blacks and Hispanics, and women with certain breast cancer gene mutations.

Researchers were able to determine this after tests in only 71 women. They calculate that tests of only 300 women with triple negative tumors are needed to give a definitive answer, and that the drug has at least a 90 percent probability of success in such patients. If more types of cancer are included, the probability of success drops to 55 percent.

The results show that "we can get early reads on something that is worth pursuing" and bail quickly on treatments that don't help, said Dr. Carlos Arteaga of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville.

Last week, another company participating in the study, Puma Biotechnology Inc., said its experimental drug neratinib also had "graduated" and would enter a definitive study. Results of the early testing will be presented at a cancer conference next year.

The San Antonio meeting is sponsored by the American Association for Cancer Research, Baylor College of Medicine and the UT Health Science Center.
© Copyright 2016 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
S&P 500 index has its best year since 1997
The stock market closed out a record year with more all-time highs on Tuesday, giving U.S. indexes their biggest annual gains in almost two decades.
6:56PM ( 2 years ago )
Colorado readies for 'Green Wednesday' pot sales
Police were adding extra patrols around pot shops in eight Colorado towns that plan to allow recreational sales to anyone over 21 on Jan. 1.
1:52PM ( 2 years ago )
Kerry seeks framework for Mideast peace talks
A senior State Department official says Secretary of State John Kerry will try this week to get Israel and the Palestinians to agree on a framework for negotiating a final peace agreement, yet cautions against raising expectations for Kerry's latest round of shuttle diplomacy.
1:35PM ( 2 years ago )
U.S. News
Ethics laws set to take effect Jan. 1 in Georgia
After dominating much of the legislative session, a set of major ethics reforms is scheduled to take effect Jan. 1.
7:04PM ( 2 years ago )
Sex offender held in Hall County for failing to register
A 47-year-old man was booked into the Hall County Jail Tuesday, being held without bond for allegedly failing to register as a sex offender, his second such arrest.
6:09PM ( 2 years ago )
Pharmacy robberies may involve same suspect
Oakwood Police Tuesday afternoon released details in a pharmacy robbery they're investigating, similar to one that happened in the Hall County Tuesday morning.
5:46PM ( 2 years ago )
Local/State News
Amid shouts of 'shame,' House GOP defeats gay rights measure
Democrats shouted "shame," but House Republicans switched their votes and defeated a measure to protect gay rights
8:03PM ( 6 days ago )
CDC director Freiden warns GOP Zika bill is inadequate
The head of the Centers for Disease Control and Prevention warned Wednesday that a House GOP measure to combat the Zika virus is inadequate to deal with the swelling threat to public health
7:36PM ( 1 week ago )
Trump unveils list of his top picks for Supreme Court
Donald Trump, the presumptive Republican nominee for president, released Wednesday a list of 11 potential Supreme Court justices he plans to vet to fill the seat of late Justice Antonin Scalia if he's elected to the White House.
3:31PM ( 1 week ago )
1st US penis transplant could bring hope to maimed soldiers
A 64-year-old cancer patient has received the nation's first penis transplant, a groundbreaking operation that may also help U.S. veterans maimed by roadside bombs
8:04PM ( 1 week ago )
States dig in against directive on transgender bathroom use
Politicians in Texas, Arkansas and elsewhere are vowing defiance over the Obama administration's new directive on transgender bathroom use
9:19PM ( 1 week ago )